Genzyme | GenomeWeb

Genzyme

Premium
Genzyme this week launched its cystic fibrosis gene-sequencing test. The company said the test can detect approximately 98 percent of the more than 1,200 disease-causing mutations in the CFTR gene.
 
Most genetic CF testing is performed by mutation panels, which detect the most common CFTR mutations. CF gene sequencing detects the most common mutations, as well as less common mutations not included in the available mutation panels.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.